サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429361

細胞および遺伝子治療の世界市場レポート 2024

Cell and Gene Therapy Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
細胞および遺伝子治療の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

細胞および遺伝子治療の市場規模は、今後数年間で指数関数的に成長すると予想されています。 2028年には23.1%の年間複合成長率（CAGR）で397億4,000万米ドルに成長すると予想されます。予測される成長は、がんや慢性疾患の有病率の増加、高齢者人口の増加、細胞および遺伝子治療への注目の高まり、ヘルスケア費の増加によって促進されます。主な動向には、CAR T細胞療法などの先進的治療法、調査イニシアチブ、戦略的提携、CRISPRなどの遺伝子編集ツールの重視、提携または買収、細胞および遺伝子治療のためのパイプライン研究の拡大、製造施設拡張への投資が含まれます。

細胞および遺伝子治療（CGT）市場の成長は、セクター内の一貫した投資と統合の取り組みによって大幅に促進されました。 CGT市場の計り知れない可能性を認識し、売上高ランキングの上位20社のバイオ医薬品企業のうち16社がCGT製品を自社のポートフォリオに統合しています。わかりやすい例としては、ファイザーが2021年12月にノースカロライナ州ダーラムに最先端の施設を設立するために6,850万米ドルという多額の投資を割り当てた。この戦略的措置は、同社の遺伝子治療能力をさらに向上させることを目的としていました。ノースカロライナ州におけるファイザーの施設拡張は、州内の複数の拠点で3,600人を超える従業員を収容し、遺伝子治療におけるエンドツーエンドの能力の強化に大きく貢献しています。着実な投資の流入とCGT生産能力の統合により、生産能力が増強され、その結果市場の成長を促進しています。

現在進行中の臨床試験の急増が、細胞および遺伝子治療市場を前進させる原動力となっています。臨床試験は、新しい治療法、介入、または診断手順の安全性と有効性を評価するための、人間の参加者が関与する極めて重要な調査研究として機能します。 細胞および遺伝子治療の領域では、これらの試験は、安全性と有効性を評価するための制御された環境を提供することで、革新的な治療法の進歩に不可欠な役割を果たします。国立衛生研究所（NIH）の一部門であるClinicalTrials.govのデータで証明されているように、登録された研究の数は、2022年の437,523件から、2023年 10月までに米国の50州すべて、221か国にわたって468,457件に大幅に増加しました。注目すべきことに、これらの研究のかなりの部分（全体の31%）である143,613件は米国内のみで実施されているのに対し、251,159件の研究（全体の54%）は米国以外の場所で実施されています。この進行中の臨床試験の数の増加は、細胞および遺伝子治療市場の成長軌道の原動力となっていることがわかります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の細胞および遺伝子治療市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 細胞治療
  • 遺伝子治療
  • 世界の細胞および遺伝子治療市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 腫瘍学
  • 皮膚科
  • 筋骨格系
  • その他の用途
  • 世界の細胞および遺伝子治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 外来手術センター
  • がん治療センター
  • 創傷ケアセンター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の細胞および遺伝子治療市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の細胞および遺伝子治療市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 細胞および遺伝子治療市場の競合情勢
  • 細胞および遺伝子治療市場の企業プロファイル
    • Biogen Inc.
    • Novartis AG
    • Gilead Sciences
    • Ionis Pharmaceuticals Inc.
    • Alnylam Pharmaceuticals Inc.

第31章 その他の大手および革新的な企業

  • ArrowHead Pharmaceuticals Inc.
  • Spark Therapeutics
  • Bluebird Bio Inc.
  • RegenexBio
  • Mesoblast Limited
  • Biocon
  • Cipla
  • Stempeutics Research Pvt. Ltd.
  • EdiGene Inc.
  • Immunochina
  • Takara Bio
  • Daiichi Sankyo Company
  • Ultragenyx Pharmaceutical Inc
  • Mitsubishi Tanabe Pharma
  • Oxford Biomedica plc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14373

Gene therapy involves delivering genetic material, typically through a carrier or vector, with the gene being taken up by the appropriate body cells. Cell therapy, on the other hand, entails introducing cells into the patient to restore proper function. Some procedures combine both cell and gene therapy.

The primary product categories in cell and gene therapies are cell therapy and gene therapy. Gene therapy in medicine focuses on modifying the genetic material of cells for therapeutic effects or disease healing by repairing damaged genetic material. Applications span oncology, dermatology, musculoskeletal treatments, and others, with utilization across sectors such as hospitals, ambulatory surgical centers, cancer care centers, wound care centers, and more.

The cell and gene therapy market research report is one of a series of new reports from The Business Research Company that provides cell and gene therapy market statistics, including global market size, regional shares, competitors with a cell and gene therapy market share, detailed cell and gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy industry. This cell and gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell & gene therapy market size has grown exponentially in recent years. It will grow from $13.81 billion in 2023 to $17.31 billion in 2024 at a compound annual growth rate (CAGR) of 25.3%. The historical growth can be attributed to an increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, a rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and an increase in pharmaceutical R&D expenditure.

The cell & gene therapy market size is expected to see exponential growth in the next few years. It will grow to $39.74 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. Forecasted growth is fueled by increasing cancer and chronic disease prevalence, a growing geriatric population, heightened focus on cell and gene therapy, and rising healthcare expenditure. Key trends include advanced therapies such as CAR T-cell therapy, research initiatives, strategic collaborations, emphasis on gene editing tools such as CRISPR, partnerships or acquisitions, expanded pipeline studies for cell and gene therapies, and investment in manufacturing facility expansion.

The growth of the cell and gene therapy (CGT) market has been significantly bolstered by consistent investment and consolidation initiatives within the sector. Recognizing the immense potential of the CGT market, 16 of the top 20 largest biopharmaceutical companies, ranked by revenue, have integrated CGT products into their portfolios. An illustrative example is Pfizer, which, in December 2021, allocated a substantial investment of $68.5 million to establish a cutting-edge facility in Durham, North Carolina. This strategic move aimed to further advance the company's gene therapy capabilities. Pfizer's facility expansion in North Carolina, accommodating over 3,600 employees across multiple sites in the state, significantly contributes to enhancing their end-to-end capabilities in gene therapy. The steady influx of investment and consolidation in CGT production capacity has resulted in an augmented production capacity, consequently fueling the market's growth.

The burgeoning number of ongoing clinical trials stands as a driving force propelling the cell and gene therapy market forward. Clinical trials serve as pivotal research studies involving human participants to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. In the realm of cell and gene therapy, these trials play an integral role in advancing these innovative therapies by providing a controlled environment to evaluate their safety and efficacy. As evidenced by data from ClinicalTrials.gov, a division of the National Institutes of Health (NIH), the number of registered studies increased significantly from 437,523 in 2022 to 468,457 across all 50 states of the United States and spanning 221 countries by October 2023. Notably, a considerable portion of these studies-143,613 (31% of the total)-are conducted solely within the U.S., while 251,159 studies (54% of the total) are conducted in non-U.S. locations. This escalating number of ongoing clinical trials signifies a driving force behind the growth trajectory of the cell and gene therapy market.

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a pivotal driver shaping the landscape of the cell and gene therapy (CGT) market. This innovative therapy combines elements of both cell and gene therapy by utilizing T cells obtained from a patient's blood, which are then genetically modified to produce specialized receptors known as chimeric antigen receptors (CARs) on their surface. These engineered T cells, equipped with modified receptors, are reintroduced into the patient's system. The modified receptors on the T cells enable them to effectively target and bind to specific surface antigens present on cancer cells, ultimately leading to the destruction of tumor cells within patients. A notable example occurred in June 2022 when Bristol-Myers Squibb Company, a US-based pharmaceutical firm, received approval from the United States Food and Drug Administration (US FDA) for Breyanzi, a CAR T cell therapy designed for treating adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma. Breyanzi stands out as a distinct CAR T cell therapy engineered from a patient's own T cells, collected and genetically reengineered into CAR T cells, subsequently administered via infusion as a one-time treatment.

Major companies operating within the cell and gene therapy market are intensifying their focus on introducing agnostic systems to gain a competitive edge. Agnostic systems encompass platforms integrated with a diverse array of cell and gene therapy (CGT) software platforms, as well as biopharmaceutical or provider-facing platforms. For instance, in April 2023, AmerisourceBergen, a US-based healthcare company, unveiled the Cell and Gene Therapy Integration Hub-a newly launched platform-agnostic system. This innovative system aims to enhance connectivity throughout the cell and gene therapy treatment journey, elevating the overall patient and provider experience. Powered by the company's customer relationship management system, the hub is designed to expedite the benefits investigation process, offer real-time insights into therapy development and transportation status, and assist in streamlining patient support coordination.

In December 2021, Novartis AG, a Switzerland-based pharmaceutical company, completed the acquisition of Gyroscope Therapeutics Holdings plc for $800 million. This strategic move adds GT005, an experimental one-time gene therapy in Phase 2 for treating geographic atrophy (GA), to Novartis' portfolio. The acquisition enhances gene therapy research capabilities and contributes to global ophthalmic innovation for treating and preventing blindness. Gyroscope Therapeutics Holdings plc is a UK-based clinical-stage biopharmaceutical company specializing in gene therapies for eye-related diseases.

Major companies operating in the cell and gene therapy market report are Biogen Inc., Novartis AG, Gilead Sciences, Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., ArrowHead Pharmaceuticals Inc., Spark Therapeutics, Bluebird Bio Inc., RegenexBio, Mesoblast Limited, Biocon, Cipla, Stempeutics Research Pvt. Ltd., EdiGene Inc., Immunochina, Takara Bio, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc., Mitsubishi Tanabe Pharma, Oxford Biomedica PLC, Santen Pharmaceutical Co., Therapeutic Innovation Australia, Merck, GenScript, Cellular Biomedicine Group, GE Healthcare, inStem, Lonza, Nikon CeLL innovation Co. Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Kite Pharma, Oxford BioTherapeutics, Freeline Therapeutics, PsiOxus Therapeutics, Herantis Pharma PLC, and AstraZeneca.

North America was the largest region in the cell and gene therapy market in 2023. The regions covered in the cell and gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cell and gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The cell and gene therapy market includes revenues earned by entities treating cancer, cystic fibrosis, heart disease, diabetes, haemophilia, and AIDS. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell and Gene Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell and gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cell and gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell and gene therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Product: Cell Therapy; Gene Therapy
  • 2) By Application: Oncology; Neurological Disorders; Other Applications
  • 3) By End User: Hospitals; Ambulatory Surgical Centers; Cancer Care Centers; Wound Care Centers; Other End-Users
  • Companies Mentioned: Biogen Inc.; Novartis AG; Gilead Sciences; Ionis Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cell and Gene Therapy Market Characteristics

3. Cell and Gene Therapy Market Trends And Strategies

4. Cell and Gene Therapy Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Cell and Gene Therapy Market Size and Growth

  • 5.1. Global Cell and Gene Therapy Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Cell and Gene Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Cell and Gene Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Cell and Gene Therapy Market Segmentation

  • 6.1. Global Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cell Therapy
  • Gene Therapy
  • 6.2. Global Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oncology
  • Dermatology
  • Musculoskeletal
  • Other Applications
  • 6.3. Global Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Care Centers
  • Wound Care Centers
  • Other End-Users

7. Cell and Gene Therapy Market Regional And Country Analysis

  • 7.1. Global Cell and Gene Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Cell and Gene Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Cell and Gene Therapy Market

  • 8.1. Asia-Pacific Cell and Gene Therapy Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Cell and Gene Therapy Market

  • 9.1. China Cell and Gene Therapy Market Overview
  • 9.2. China Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Cell and Gene Therapy Market

  • 10.1. India Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Cell and Gene Therapy Market

  • 11.1. Japan Cell and Gene Therapy Market Overview
  • 11.2. Japan Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Cell and Gene Therapy Market

  • 12.1. Australia Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Cell and Gene Therapy Market

  • 13.1. Indonesia Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Cell and Gene Therapy Market

  • 14.1. South Korea Cell and Gene Therapy Market Overview
  • 14.2. South Korea Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Cell and Gene Therapy Market

  • 15.1. Western Europe Cell and Gene Therapy Market Overview
  • 15.2. Western Europe Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Cell and Gene Therapy Market

  • 16.1. UK Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Cell and Gene Therapy Market

  • 17.1. Germany Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Cell and Gene Therapy Market

  • 18.1. France Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Cell and Gene Therapy Market

  • 19.1. Italy Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Cell and Gene Therapy Market

  • 20.1. Spain Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Cell and Gene Therapy Market

  • 21.1. Eastern Europe Cell and Gene Therapy Market Overview
  • 21.2. Eastern Europe Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Cell and Gene Therapy Market

  • 22.1. Russia Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Cell and Gene Therapy Market

  • 23.1. North America Cell and Gene Therapy Market Overview
  • 23.2. North America Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Cell and Gene Therapy Market

  • 24.1. USA Cell and Gene Therapy Market Overview
  • 24.2. USA Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Cell and Gene Therapy Market

  • 25.1. Canada Cell and Gene Therapy Market Overview
  • 25.2. Canada Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Cell and Gene Therapy Market

  • 26.1. South America Cell and Gene Therapy Market Overview
  • 26.2. South America Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Cell and Gene Therapy Market

  • 27.1. Brazil Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Cell and Gene Therapy Market

  • 28.1. Middle East Cell and Gene Therapy Market Overview
  • 28.2. Middle East Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Cell and Gene Therapy Market

  • 29.1. Africa Cell and Gene Therapy Market Overview
  • 29.2. Africa Cell and Gene Therapy Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Cell and Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Cell and Gene Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Cell and Gene Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Cell and Gene Therapy Market Competitive Landscape
  • 30.2. Cell and Gene Therapy Market Company Profiles
    • 30.2.1. Biogen Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Gilead Sciences
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Ionis Pharmaceuticals Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Alnylam Pharmaceuticals Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Cell and Gene Therapy Market Other Major And Innovative Companies

  • 31.1. ArrowHead Pharmaceuticals Inc.
  • 31.2. Spark Therapeutics
  • 31.3. Bluebird Bio Inc.
  • 31.4. RegenexBio
  • 31.5. Mesoblast Limited
  • 31.6. Biocon
  • 31.7. Cipla
  • 31.8. Stempeutics Research Pvt. Ltd.
  • 31.9. EdiGene Inc.
  • 31.10. Immunochina
  • 31.11. Takara Bio
  • 31.12. Daiichi Sankyo Company
  • 31.13. Ultragenyx Pharmaceutical Inc
  • 31.14. Mitsubishi Tanabe Pharma
  • 31.15. Oxford Biomedica plc

32. Global Cell and Gene Therapy Market Competitive Benchmarking

33. Global Cell and Gene Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cell and Gene Therapy Market

35. Cell and Gene Therapy Market Future Outlook and Potential Analysis

  • 35.1 Cell and Gene Therapy Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Cell and Gene Therapy Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Cell and Gene Therapy Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer